SQZ Biotechnologies’ cell engineering platform allows one to deliver a diverse set of materials into patient cells, providing the opportunity to alter numerous cell functions.
SQZ Founder and CEO. Lead inventor of the CellSqueeze technology. Selected as one of the 30 Under 30 in Healthcare by Forbes in 2015.
SQZ Founder. MIT Chemical Engineering Department Chair. Established leader in fabrication, testing, and integration of microsystems.
Highly valued board member for several biotechnology companies. Former President and Head of Global Oncology at Pfizer.
Polaris Partner and former Pfizer executive. Named one of Fortune's 50 most powerful women in business in 2013.
President & Chief Executive Office of Q State Biosciences. Investment manager for over 27 years. Started and financed the growth of multiple companies.
Principal at NanoDimension. Involved in deal sourcing, due diligence and deal structuring focusing on NanoDimension's life sciences investments.
SQZ Founder. MIT Koch Institute Professor. Most cited engineer in history renowned for his contributions to the fields of drug delivery and tissue engineering.
Chief Scientific Officer of Relay Therapeutics. Former CTO and SAB Chair of Vertex. Over 25 years of leadership experience in the biomedical field. Key contributor to seven marketed drugs.
In addition to co-developing the anti-PD1 checkpoint blockade, Dr. Sharpe co-directs The Evergrande Center for Immunologic Diseases at Harvard and Brigham and Women’s Hospital
Mallinckrodt Professor of Immunopathology at Harvard Medical School and leader in understanding the regulation and function of immune cells
Director of The Koch Institute for Cancer Research and MIT professor breaking new ground in gene targeting strategies for cancer
In addition to positions at MIT, The Koch Institute, and The Ragon Institute, Dr. Irvine is investigating immune engineering strategies for The Howard Hughes Medical Institute
MIT professor and leader in MEMS, immune profiling and monitoring, Dr. Love holds positions at the Broad and Ragon Institutes
Thought leader in immune tolerance research. Among his contributions are the discovery of MHC Class II antigens and the initiation of the first successful clinical trials of transplantation tolerance. Currently directs transplantation research at both Columbia and MGH.
Chair of the Department of Immunology at the University of Pittsburgh School of Medicine and leader in studies of B cell immune responses, B cell memory and systemic autoimmune diseases like SLE.